ARTV

SEC source: 0001193125-26-416953 · ownership.xml · nonDerivative · entry 1

Aslan Fred · CIK 0001909362 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,519,606

F1 · kind: The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 13, 2026.

F2 · price: The weighted average sale price for the transaction reported was $7.1977, and the range of prices were between $6.92 and $7.36. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001193125-26-415531 · ownership.xml · nonDerivative · entry 1

Horan Christopher · CIK 0001736819 · Chief Tech Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 312,744

F1 · shares: The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001193125-26-415529 · ownership.xml · nonDerivative · entry 1

Bush Jennifer · CIK 0001621152 · COO, CLO, Compliance Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 366,159

F1 · shares: The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001193125-26-415528 · ownership.xml · nonDerivative · entry 1

Banerjee Subhashis · CIK 0002065633 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,848

F1 · shares: The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001193125-26-415527 · ownership.xml · nonDerivative · entry 1

Aslan Fred · CIK 0001909362 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,543,069

F1 · shares: The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001193125-26-392025 · ownership.xml · derivative · entry 2

Aslan Fred · CIK 0001909362 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 315,000

Underlying: Common Stock · 315,000 shares

Expires 2036-09-14

F2 · derivative.exercise_date: Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period.

SEC source: 0001193125-26-392025 · ownership.xml · nonDerivative · entry 1

Aslan Fred · CIK 0001909362 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,604,765

F1 · shares: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.

SEC source: 0001193125-26-391012 · ownership.xml · derivative · entry 2

Aslan Fred · CIK 0001909362 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,000

Underlying: Common Stock · 155,000 shares

Expires 2036-09-09

F2 · derivative.exercise_date: Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period.

SEC source: 0001193125-26-391012 · ownership.xml · nonDerivative · entry 1

Aslan Fred · CIK 0001909362 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,494,765

F1 · shares: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.

SEC source: 0001231919-26-001173 · form4-09142026_100941.xml · derivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 16,250

Underlying: Common Stock · 16,250 shares

Expires 2036-09-09

F1 · derivative.exercise_date: Represents the grant of a stock option to Laura Stoppel in connection with her service on the Issuer's board of directors. The shares subject to the option will vest on the earlier of September 10, 2027 or the date of the Issuer's 2027 annual stockholder meeting, subject to Dr. Stoppel's continuous service as a director through such vesting date.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his pecuniary interest therein.

F3 · ownership.nature: Under Dr. Stoppel's arrangement with the Adviser, Dr. Stoppel holds the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund III and the Account. Dr. Stoppel is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

SEC source: 0001193125-26-390558 · ownership.xml · derivative · entry 1

Stoppel Laura · CIK 0001865119 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,250

Underlying: Common Stock · 16,250 shares

Expires 2036-09-09

F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

F2 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying common stock.

SEC source: 0001193125-26-390540 · ownership.xml · derivative · entry 1

Sorg Elaine K. · CIK 0001832571 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,250

Underlying: Common Stock · 16,250 shares

Expires 2036-09-09

F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

SEC source: 0001193125-26-390534 · ownership.xml · derivative · entry 1

HOUGEN ELIZABETH L · CIK 0001074773 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,250

Underlying: Common Stock · 16,250 shares

Expires 2036-09-09

F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

SEC source: 0001193125-26-390531 · ownership.xml · derivative · entry 1

DANIELS BRIAN · CIK 0001428698 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,250

Underlying: Common Stock · 16,250 shares

Expires 2036-09-09

F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

SEC source: 0001193125-26-390527 · ownership.xml · derivative · entry 1

Baker Daniel G. · CIK 0002046802 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,250

Underlying: Common Stock · 16,250 shares

Expires 2036-09-09

F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

SEC source: 0001193125-26-390524 · ownership.xml · derivative · entry 1

MOORE ALISON · CIK 0001754937 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,250

Underlying: Common Stock · 16,250 shares

Expires 2036-09-09

F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

SEC source: 0001193125-26-389514 · ownership.xml · derivative · entry 2

Miralles Gines Diego · CIK 0001773413 · President & Head of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,000

Underlying: Common Stock · 135,000 shares

Expires 2036-09-08

F2 · derivative.exercise_date: Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period.

SEC source: 0001193125-26-389514 · ownership.xml · nonDerivative · entry 1

Miralles Gines Diego · CIK 0001773413 · President & Head of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 122,500

F1 · shares: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.

SEC source: 0001193125-26-389512 · ownership.xml · derivative · entry 2

Horan Christopher · CIK 0001736819 · Chief Tech Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2036-09-08

F2 · derivative.exercise_date: Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period.

SEC source: 0001193125-26-389512 · ownership.xml · nonDerivative · entry 1

Horan Christopher · CIK 0001736819 · Chief Tech Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 323,084

F1 · shares: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.

SEC source: 0001193125-26-389511 · ownership.xml · derivative · entry 2

Bush Jennifer · CIK 0001621152 · COO, CLO, Compliance Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,000

Underlying: Common Stock · 135,000 shares

Expires 2036-09-08

F2 · derivative.exercise_date: Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period.

SEC source: 0001193125-26-389511 · ownership.xml · nonDerivative · entry 1

Bush Jennifer · CIK 0001621152 · COO, CLO, Compliance Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 374,529

F1 · shares: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.

SEC source: 0001193125-26-389510 · ownership.xml · derivative · entry 2

Banerjee Subhashis · CIK 0002065633 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2036-09-08

F2 · derivative.exercise_date: Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period.

SEC source: 0001193125-26-389510 · ownership.xml · nonDerivative · entry 1

Banerjee Subhashis · CIK 0002065633 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,947

F1 · shares: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.

SEC source: 0001193125-26-386431 · ownership.xml · nonDerivative · entry 1

Aslan Fred · CIK 0001909362 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,449,765

F1 · kind: The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 13, 2026.

F2 · price: The weighted average sale price for the transaction reported was $10.9158, and the range of prices were between $10.72 and $11.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001231919-26-001152 · form4-09082026_100904.xml · derivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 13,750

Underlying: Common Stock · 13,750 shares

Expires 2036-09-07

F1 · derivative.exercise_date: Represents the grant of a stock option to Laura Stoppel pursuant to the Issuer's non-employee director compensation policy. The shares subject to the option will vest on the earlier of September 8, 2027 or the date of the Issuer's 2027 annual stockholder meeting, subject to Dr. Stoppel's continuous service as a director through such vesting date.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his pecuniary interest therein.

F3 · ownership.nature: Under Dr. Stoppel's arrangement with the Adviser, Dr. Stoppel holds the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund III and the Account. Dr. Stoppel is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

SEC source: 0001193125-26-385419 · ownership.xml · derivative · entry 1

Stoppel Laura · CIK 0001865119 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,750

Underlying: Common Stock · 13,750 shares

Expires 2036-09-07

F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

SEC source: 0001193125-26-385418 · ownership.xml · derivative · entry 1

Sorg Elaine K. · CIK 0001832571 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,750

Underlying: Common Stock · 13,750 shares

Expires 2036-09-07

F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

SEC source: 0001193125-26-385416 · ownership.xml · derivative · entry 1

HOUGEN ELIZABETH L · CIK 0001074773 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,750

Underlying: Common Stock · 13,750 shares

Expires 2036-09-07

F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

SEC source: 0001193125-26-385414 · ownership.xml · derivative · entry 1

DANIELS BRIAN · CIK 0001428698 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,750

Underlying: Common Stock · 13,750 shares

Expires 2036-09-07

F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

SEC source: 0001193125-26-385412 · ownership.xml · derivative · entry 1

Baker Daniel G. · CIK 0002046802 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,750

Underlying: Common Stock · 13,750 shares

Expires 2036-09-07

F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

SEC source: 0001193125-26-385409 · ownership.xml · derivative · entry 1

MOORE ALISON · CIK 0001754937 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,750

Underlying: Common Stock · 13,750 shares

Expires 2036-09-07

F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

SEC source: 0001193125-26-383625 · ownership.xml · nonDerivative · entry 1

Horan Christopher · CIK 0001736819 · Chief Tech Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 283,084

F1 · shares: The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The weighted average sale price for the transaction reported was $11.1555, and the range of prices were between $11.0301 and $11.1556. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001193125-26-383621 · ownership.xml · nonDerivative · entry 1

Bush Jennifer · CIK 0001621152 · COO, CLO, Compliance Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 329,529

F1 · shares: The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The weighted average sale price for the transaction reported was $11.1555, and the range of prices were between $11.0350 and $11.1556. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001193125-26-383619 · ownership.xml · nonDerivative · entry 1

Banerjee Subhashis · CIK 0002065633 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,947

F1 · shares: The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

SEC source: 0001193125-26-383618 · ownership.xml · nonDerivative · entry 1

Aslan Fred · CIK 0001909362 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,473,194

F1 · shares: The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The weighted average sale price for the transaction reported was $11.1555, and the range of prices were between $11.0270 and $11.1556. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001193125-26-377207 · ownership.xml · derivative · entry 3

Banerjee Subhashis · CIK 0002065633 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 74,265

Underlying: Common Stock · 5,306 shares

Expires 2035-04-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026.

F3 · derivative.exercise_date: 25% of the shares initially subject to the option vested and became exercisable on April 8, 2026, and the balance of the shares subject to the option are vesting and becoming exercisable at a rate of 1/36th per month over the following 36 months.

SEC source: 0001193125-26-377207 · ownership.xml · nonDerivative · entry 2

Banerjee Subhashis · CIK 0002065633 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 142,047

F1 · kind: The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026.

F2 · price: The weighted average sale price for the transaction reported was $12.0087, and the range of prices were between $12.00 and $12.05, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001193125-26-377207 · ownership.xml · nonDerivative · entry 1

Banerjee Subhashis · CIK 0002065633 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 150,269

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026.

SEC source: 0001193125-26-357383 · ownership.xml · derivative · entry 3

Banerjee Subhashis · CIK 0002065633 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 79,571

Underlying: Common Stock · 429 shares

Expires 2035-04-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026.

F2 · derivative.exercise_date: 25% of the shares initially subject to the option vested and became exercisable on April 8, 2026, and the balance of the shares subject to the option are vesting and becoming exercisable at a rate of 1/36th per month over the following 36 months.

SEC source: 0001193125-26-357383 · ownership.xml · nonDerivative · entry 2

Banerjee Subhashis · CIK 0002065633 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 144,963

F1 · kind: The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026.

SEC source: 0001193125-26-357383 · ownership.xml · nonDerivative · entry 1

Banerjee Subhashis · CIK 0002065633 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 145,392

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026.

SEC source: 0001231919-26-000817 · form4-07312026_090755.xml · nonDerivative · entry 2

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 17,329,570

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.82 to $9.97 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001231919-26-000817 · form4-07312026_090755.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 17,304,626

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.84 to $10.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

F3 · ownership.nature: Held directly by the Fund.

SEC source: 0001231919-26-000808 · form4-07282026_090756.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 17,283,802

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.96 to $10.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

F3 · ownership.nature: Held directly by the Fund.

SEC source: 0001231919-26-000791 · form4-07242026_010725.xml · nonDerivative · entry 3

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 17,242,483

F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.40 to $10.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

F3 · ownership.nature: Held directly by the Fund.

SEC source: 0001231919-26-000791 · form4-07242026_010725.xml · nonDerivative · entry 2

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 17,182,603

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.72 to $10.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

F3 · ownership.nature: Held directly by the Fund.

SEC source: 0001231919-26-000791 · form4-07242026_010725.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 17,098,479

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.16 to $10.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

F3 · ownership.nature: Held directly by the Fund.

SEC source: 0001231919-26-000774 · form4-07202026_100743.xml · nonDerivative · entry 2

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 16,977,927

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.88 to $9.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

F3 · ownership.nature: Held directly by the Fund.

SEC source: 0001231919-26-000774 · form4-07202026_100743.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 16,970,045

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.79 to $9.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

F3 · ownership.nature: Held directly by the Fund.